

# Table of Contents

## Editorial Board

### EDITOR

James A. Taylor, Seattle, WA

### DEPUTY EDITOR

Leslie L. Barton, Tucson, AZ

### CME QUESTION EDITOR

Robert Wittler, Wichita, KS

### EDITORIAL BOARD

Rana Alissa, Jacksonville, FL

Deborah Badawi, Baltimore, MD

Kirsten Bechtel, New Haven, CT

Rebecca Brady, Cincinnati, OH

Susan L. Bratton, Salt Lake City, UT

Meghan Candee, Salt Lake City, UT

Marilynn Chan, San Francisco, CA

Benjamin Doolittle, New Haven, CT

Mike Dubik, Portsmouth, VA

Patricia Fechner, Seattle, WA

Jason Goldberg, Memphis, TN

William L. Hennrikus, Hershey, PA

Gloria Higgins, Columbus, OH

Mary-Jane Staba Hogan, New Haven, CT

Daniel Lesser, San Diego, CA

Meghna Raphael, Houston, TX

Philip Rosenthal, San Francisco, CA

Cheryl Sanchez-Kazi, Loma Linda, CA

Isabelle Von Kohorn, Washington, DC

Jeffrey Winer, Memphis, TN

**Mission:** To provide pediatricians with timely synopses and critiques of important new studies relevant to pediatric practice, reviewing methodology, significance, and practical impact, as part of ongoing CME activity.

AAP *Grand Rounds*<sup>TM</sup> is published monthly by the American Academy of Pediatrics, 345 Park Blvd., Itasca, IL 60143. Copyright ©2022 American Academy of Pediatrics. All rights reserved.

**Postmaster:** Send address changes to *AAP Grand Rounds*, American Academy of Pediatrics, Customer Service Center, 345 Park Blvd., Itasca, IL 60143.

### ISSN Numbers

Print: 1099-6605

Online: 1556-326X

**Customer Service and Renewals:** (866) 843-2271

**Email Address:** [grandrounds@aap.org](mailto:grandrounds@aap.org)

**Subscription Rates:** AAP member \$102/year; non-member \$127/year (12 issues), including up to 18 AMA PRA Category 1 credit(s)<sup>TM</sup>.

**Managing Editor:** Will Larkin

**Production:** LSD DESIGN LLC

**Editorial Associate:** Carol Frost

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

**Rebecca Brady, MD** (Editorial Board Member) has disclosed research grant relationship with Astra Zeneca, Pfizer, PATH. **Mike Dubik, MD** (Editorial Board Member) has disclosed stock ownership in Gilead Sciences, Amgen, Avid, Biosciences, Mednax. **Patricia Fechner, MD** (Editorial Board Member) has disclosed stock ownership in Abbott Laboratories, Abbvie; member of advisory board for Neurocrine Biosciences; Principal Investigator with Neurocrine Biosciences, Spruce Bioscience and Lumos. Consultant Relationships with Easton Pharmaceuticals. **Philip Rosenthal, MD** (Editorial Board Member) has disclosed research grant relationship with Gilead, Abbvie, Merck, Retrophin, Arrowhead & Mirum; paid consultant relationship with Retrophin and Dicerna; consultant relationships with Albireo, Amby, Audentes, BioMarin, Encoded, MedinCell, Mirum & Takeda. Principal Investigator relationship with Albireo. **Cheryl Sanchez-Kazi, MD** (Editorial Board Member) has disclosed she is a site PI for Kaneka Pharma America & NIH. **James Taylor, MD** (Editor in Chief) has disclosed an employee relationship with Google.

## MEDICINE-PEDIATRICS

**p51** Effectiveness and Safety of Emollients for Childhood Eczema

## CARDIOLOGY

**p52** Increased Prevalence of Congenital Heart Disease With Hypospadias

## GASTROENTEROLOGY

**p53** Diagnosing Celiac Disease Using Antitissue Transglutaminase Titer

## CRITICAL CARE

**p54** Phenotype-Directed Biologic Therapy of Severe Asthma

## INFECTIOUS DISEASES

**p55** Respiratory Viruses and Community-Acquired Pneumonia

## HOSPITAL MEDICINE

**p56** Increasing Rate of Pediatric Rhabdomyolysis Admissions

## NEPHROLOGY

**p57** Angioplasty Therapy of Renovascular Hypertension in Young Children

## HEMATOLOGY-ONCOLOGY

**p58** Variables Related to HPV Vaccination Rates in Teens

## EMERGENCY MEDICINE

**p59** Disparities in Care of Children With Acute Gastroenteritis

## CME/MOC INFORMATION

2022 *AAP Grand Rounds* subscribers may claim a maximum of 18 AMA PRA Category 1 Credit(s)<sup>TM</sup> upon completion of all the quiz questions over the course of their annual subscription. On a monthly basis, members may claim a maximum of 1.5 AMA PRA Category 1 Credit(s)<sup>TM</sup>.

The American Academy of Pediatrics (AAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AAP designates this enduring material for a maximum of 18.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is acceptable for a maximum of 18.0 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit<sup>TM</sup> from organizations accredited by ACCME. Physician assistants may receive a maximum of 18.0 hours of Category 1 credit for completing this program.

This program is accredited for 18.0 NAPNAP CE contact hours of which 0 contain pharmacology (Rx), (0 related to psychopharmacology) (0 related to controlled substances), content per the National Association of Pediatric Nurse Practitioners (NAPNAP) Continuing Education Guidelines.

This activity is approved for 18.0 MOC Part 2 points by the American Board of Pediatrics through the AAP MOC Portfolio Program. All points will be awarded (or must be claimed) based on the MOC activity completion date, which is the date MOC requirements were met. All deadlines and MOC point values should be confirmed by checking the ABP Activity Catalog within each physician's ABP Portfolio. Consult your ABP portfolio at [www.abp.org](http://www.abp.org) for details about your specific certification requirements. For questions about how to access this activity, contact [MOCPortfolio@aap.org](mailto:MOCPortfolio@aap.org).

*If you do not successfully complete all components of the activity and evaluation assessment ABP MOC Part 2 Points will not be awarded.* Learners must complete a minimum of 5 quizzes from the 2022 issues, with a minimum passing score of 70% on each, to earn 18 MOC Part 2 points.

No product-specific advertising of any type appears in this activity. No links to product websites appear in this activity.